Capricor Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.
Current Price
$29.01
+7.76%Profile
Valuation (TTM)
Market Cap$1.67B
P/E-14.56
EV—
P/B5.46
Shares Out57.51M
P/Sales—
Revenue$0.00
EV/EBITDA—
Capricor Therapeutics Inc (CAPR) Stock Analysis
Market Cap$1.67B
Current Price$29.01
P/E Ratio-14.56
Forward P/E—
PEG Ratio-1.29
EPS$-2.26
Book Value$5.32
P/B Ratio5.46
CAPR Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 273M
Revenue
1M
FY19
—
FY20
—
FY21
3M
FY22
25M
FY23
22M
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
CAPR 52-Week Range
$4.60
$35.34
50-Day MA: $31.83200-Day MA: $19.36
Did you know?
Price sits at 79% of its 52-week range.
Capricor Therapeutics Inc (CAPR) Financial Summary
Capricor Therapeutics Inc (CAPR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $29.01 with a market capitalization of $1.67B.
Key valuation metrics include a P/E ratio of -14.56, price-to-book ratio of 5.46, and EPS of $-2.26. and return on equity of -37.5%.
CAPR Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $1.67B |
| P/E Ratio | -14.56 |
| EPS | $-2.26 |
| P/B Ratio | 5.46 |
| Return on Equity | -37.5% |
| Debt/Equity | 0.05 |
CAPR Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $1.01M | $-7.64M |
| FY20 | $310250.00 | $-13.66M |
| FY21 | $244898.00 | $-20.02M |
| FY22 | $2.55M | $-29.02M |
| FY23 | $25.18M | $-22.29M |
| FY24 | $22.27M | $-40.47M |
| FY25 | $0.00 | $-105.04M |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.
CAPR Free Cash Flow
Capricor Therapeutics Inc generated $-81.54M in trailing twelve-month free cash flow, representing an FCF yield of -4.89%. This low FCF yield may reflect heavy reinvestment or growth spending.
CAPR Shares Outstanding
Capricor Therapeutics Inc has 0.06 billion shares outstanding at a share price of $29.01, giving it a market capitalization of $1.67B.